Roche China CEO preps for a move to Merck KGaA while US Merck adds to C-suite; Succession plan finalized for EVPs retiring from Sanofi

Hong Chow

→ Beginning Oct. 1, Roche China CEO Hong Chow will be head of China & international for Merck KGaA’s healthcare business, a position that also encompasses Japan, Europe, Latin America, Asia-Pacific, the Middle East, Africa and Russia. The multi-pronged position also has Chow leading the cardiovascular metabolism & endocrinology franchise and the Global Business Innovation (GBI) unit. A Bayer alum, Chow has helmed Roche China since 2015.

“My years with Roche have been just incredible and I am forever grateful for the opportunity to work with so many amazing people in China and around the world to deliver so many more innovative drugs to Chinese patients in an unimaginable speed,” Chow said on LinkedIn. “At the same time, I am very excited to start the new chapter in October with Merck to make a broader impact to patients and society…
Click here to view original post